Preclinical evidence supports sotagliflozin’s superior efficacy in attenuating salt-induced kidney damage

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, initially developed to treat type 2 diabetes, have significant heart- and kidney- protective effects. In the kidney, SGLT2 reabsorbs approximately 97% offiltered glucose in the S1 and S2 segments of the proximal tubule, while SGLT1reabsorbs the remainder in the S3 segment.

To continue reading click here